[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
1. Machlenkin S, Melzer E, Idelevich E, Ziv-Sokolovsky N, Klein Y, Kashtan H: Endoscopic ultrasound: doubtful accuracy for restaging esophageal cancer after preoperative chemotherapy. Isr Med Assoc J; 2009 Mar;11(3):166-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic ultrasound: doubtful accuracy for restaging esophageal cancer after preoperative chemotherapy.
  • BACKGROUND: The role of endoscopic ultrasound in evaluating the response of esophageal cancer to neoadjuvant chemotherapy is controversial.
  • The initial staging was determined by chest and abdominal computed tomography and EUS.
  • Upon completion of the chemotherapy, patients were restaged and then underwent esophagectomy.
  • RESULTS: NAC was conducted in 20 patients with initial stage IIB and III carcinoma of the esophagus (study group).
  • Post-chemotherapy EUS accurately predicted the surgical pathology stage in 6 patients (30%).
  • However, it is not a reliable tool for restaging esophageal cancer after NAC and it cannot predict response to chemotherapy.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Esophagectomy. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging / methods. Postoperative Period. Reproducibility of Results. Retrospective Studies

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544707.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


2. Markogiannakis H, Theodorou D, Toutouzas KG, Larentzakis A, Pattas M, Bousiotou A, Papacostas P, Filis K, Katsaragakis S: Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature. J Med Case Rep; 2008;2:15

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell carcinoma arising in Barrett's esophagus: a case report and review of the literature.
  • INTRODUCTION: Gastrointestinal tract small cell carcinoma is an infrequent and aggressive neoplasm that represents 0.1-1% of gastrointestinal malignancies.
  • Very few cases of small cell esophageal carcinoma arising in Barrett's esophagus have been reported in the literature.
  • An extremely rare case of primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus is herein presented.
  • Esophagogastroscopy revealed an ulceroproliferative, intraluminar mass in the distal esophagus obstructing the esophageal lumen.
  • Contrast-enhanced chest and abdominal computed tomography demonstrated a large tumor of the distal third of the esophagus without any lymphadenopathy or distant metastasis.
  • Preoperative chemotherapy with cisplatine and etoposide for 3 months resulted in a significant reduction of the tumor.
  • Histopathology revealed a primary small cell carcinoma of the distal third of the esophagus arising from dysplastic Barrett's esophagus.
  • The patient received another 3 month course of postoperative chemotherapy with the same agents and remained free of disease at 12 month review.
  • CONCLUSION: Although small cell esophageal carcinoma is rare and its association with dysplastic Barrett's esophagus is extremely infrequent, the high carcinogenic risk of Barrett's epithelium should be kept in mind.
  • Prognosis is quite unfavorable; a better prognosis might be possible with early diagnosis and treatment strategies incorporating chemotherapy along with oncological radical surgery and/or radiotherapy as part of a multimodality approach.
  • Since treatment protocols are not well established due to the rarity of the neoplasm, multi-institutional studies are needed to obtain sufficiently large populations for investigation and optimization of therapy of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1999 Nov;123(11):1123 [10539923.001]
  • [Cites] Diagn Cytopathol. 2000 Sep;23(3):180-2 [10945905.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):1-5 [12507278.001]
  • [Cites] Chest. 1995 Jan;107(1):179-81 [7813272.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2003 Jun;51(6):259-62 [12831243.001]
  • [Cites] J Pathol Bacteriol. 1952 Oct;64(4):889-91 [13000600.001]
  • [Cites] Ann Thorac Surg. 2002 Dec;74(6):1924-7 [12643374.001]
  • (PMID = 18211708.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2263060
  •  go-up   go-down


3. Tobari S, Ikeda Y, Kurihara H, Takami H, Okinaga K, Kodaira S: Effective treatment with chemotherapy and surgery for advanced small cell carcinoma of the esophagus. Hepatogastroenterology; 2004 Jul-Aug;51(58):1027-9
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment with chemotherapy and surgery for advanced small cell carcinoma of the esophagus.
  • A 78-year-old man reported a persistent midthoracic pain, mild dysphagia, and an abdominal distention.
  • An abdominal computed tomography scan showed massive ascites, extensive paracardial mass, a large mass which invaded the pancreas, and a mass of multiple para-aortic lymphadenopathies which involved the superior mesenteric artery.
  • An upper gastrointestinal endoscopic study revealed an infiltrative, ulcerating tumor of the lower esophagus.
  • Histological study of the biopsy specimens from esophageal tumor showed small cell carcinoma.
  • After combination chemotherapy, an abdominal computed tomography scan showed a disappearance of asites, a partial response reduction of paragastric mass, peripancreatic mass and para-aortic lymphadenopathies.
  • Histological study of the biopsy specimens from esophageal tumor showed a viable small cell carcinoma.
  • In June 2001, the patient underwent lower esophagectomy and proximal gastrectomy combined with splenectomy and distal pancreatectomy through an abdominal approach.
  • Histological findings of the resected specimen showed that the esophageal tumor was a small cell carcinoma which invaded into the submucosal layer, and both paracardial and peripancreatic tumors, and all lymph nodes had no cancer cells.
  • The patient's postoperative recovery was uneventful and discharged without aggressive chemotherapy postoperatively.
  • However, he eventually died of progression of the metastasis 21 months after first detection of the carcinoma.
  • Patients with esophageal small cell carcinoma treated with surgery following chemotherapy and/or radiotherapy have been reported to survive longer than those treated with chemotherapy and/or radiotherapy.
  • Therefore, surgical resection may be recommended as the second therapy that occasionally produces long-term remission and possibly long-term survival for patients with small cell carcinoma of the esophagus.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / surgery. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / surgery. Esophagectomy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Etoposide / administration & dosage. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239239.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Makino H, Tajiri T, Onda M, Sasajima K, Miyashita M, Nomura T, Maruyama H, Nagasawa S, Tsuchiya Y, Hagiwara N, Yamashita K, Takubo K: Effectiveness of preoperative chemotherapy using carboplatin (CBDCA) and surgery against an esophageal small cell carcinoma. Dis Esophagus; 2002;15(3):237-41
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of preoperative chemotherapy using carboplatin (CBDCA) and surgery against an esophageal small cell carcinoma.
  • Radiologic and endoscopic examination disclosed a 2.0-cm exophytic tumor in the middle third of the esophagus.
  • Computed tomography of the chest, abdomen, and cervical region was performed, as were gallium and bone scintigraphy.
  • After neoadjuvant chemotherapy with carboplatin (CBDCA) (400 mg/m2) and etoposide (VP-16) (100 mg/m2), endoscopy and barium-swallow esophagography showed regression.
  • Thoracic esophagectomy then was performed with mediastinal, abdominal and cervical lymph node dissection.
  • The resected tumor was polypoid, measuring 0.5 x 0.5 cm.
  • The patient has survived for more than 7 months with no further treatment and no evidence of recurrent disease.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12444997.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


5. Shimakawa T, Naritaka Y, Asaka S, Isohata N, Yamaguchi K, Murayama M, Konno S, Katsube T, Ogawa K, Ide H: A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy). Anticancer Res; 2010 Jan;30(1):221-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
  • Therefore, effective neoadjuvant adjuvant treatment is necessary to achieve successful radical resection.
  • The use of neoadjuvant chemotherapy of docetaxel, cisplatin (CDOP) and 5-fluorouracil (5-FU) (DCF) in an advanced case is reported.
  • The patient (a 67-year-old female) was diagnosed with esophageal cancer, T3, N4, M0, stage IVa with a large number of lymph node metastases in the mediastinum and in the abdominal cavity.
  • Neoadjuvant DCF chemotherapy was initiated in August 2006.
  • A complete response of the lymph node metastases in the abdominal cavity and a partial response of the esophageal lesion were achieved.
  • The surgical procedure included a right thoracolaparotomy followed by a subtotal excision of the esophagus and two-field lymph node dissection.
  • The histological efficacy of the chemotherapy was determined to be grade 1a.
  • Two additional courses of DCF therapy were administered followed by postoperative adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Staging. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150639.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Yabusaki H, Nashimoto A, Tanaka O: [A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion]. Gan To Kagaku Ryoho; 2002 Jan;29(1):119-23
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A complete response after neoadjuvant chemotherapy for advanced gastric cancer with esophageal invasion].
  • The patient was a 65-year-old woman with type 3 gastric cancer (por) in the upper third of the stomach invading esophagus.
  • Because of No. 16 lymph node swelling on abdominal CT examination, she was treated with FLP (5-fluorouracil + Leucovorin + cisplatin) as a neoadjuvant chemotherapy (NAC).
  • The activities of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) in the primary tumors upon endoscopic examination were 2.72 pmol/g tissue and 129.1 pmol/mg/min, respectively.
  • NAC by combination of FLP is thought to be effective for the treatment of highly advanced gastric cancer, especially in cases with locally advanced disease and lymph node metastasis such as the present.
  • Although no relations were seen between NAC effects and TS, DPD activities and TSIR in primary tumors in 12 gastric cancer patients, the survival rate of a low DPD activity group was significantly better than a high group in 106 cases undergoing adjuvant chemotherapy including 5-FU after surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esophageal Neoplasms / pathology. Lymph Nodes / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Dihydrouracil Dehydrogenase (NADP). Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Neoadjuvant Therapy. Neoplasm Invasiveness. Oxidoreductases / metabolism. Remission Induction. Thymidylate Synthase / metabolism

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816467.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 1.- / Oxidoreductases; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; PFL protocol
  •  go-up   go-down


7. Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N: Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study. Dis Esophagus; 2008;21(6):496-501
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
  • This retrospective study evaluated the safety and efficacy of combination chemotherapy using docetaxel and nedaplatin in an outpatient setting compared with those of chemotherapy using cisplatin (CDDP) and 5-Fu under hospitalization.
  • Subjects comprised 21 patients who had been diagnosed with recurrent esophageal squamous cell carcinoma (ESCC), with 10 patients receiving combination chemotherapy comprising CDDP and 5-fluorouracil (5-Fu) under hospitalization (FP group; n = 10), and 11 patients receiving combination chemotherapy comprising docetaxel and nedaplatin in an outpatient setting (Doc/Ned group; n = 11).
  • In the Doc/Ned group, complete response was observed in two patients (18.1%), one with liver metastasis and one with abdominal lymph node metastasis, and two (18.1%) achieved partial response.
  • With a median follow-up of 234 days in the Doc/Ned group and 279 days in the FP group, median survival time (MST) was 234 days in the Doc/Ned group and 378 days in the FP group.
  • Thus regimen based on docetaxel and nedaplatin allows administration on an outpatient basis and appears feasible for recurrent ESCC as a second-line chemotherapy.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18840134.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 15H5577CQD / docetaxel; 8UQ3W6JXAN / nedaplatin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Siewert E, Tietze L, Maintz C, Geier A, Dietrich CG, Matern S, Gartung C: [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding]. Z Gastroenterol; 2004 Mar;42(3):233-42
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GIST most frequently present with either gastrointestinal bleeding, abdominal pain or a detectable mass on physical examination or by ultrasound imaging.
  • Clinically asymptomatic tumor growth also occurs as demonstrated by the second case of a 44-year-old -woman with an incidental finding of GIST during surgery of the esophagus.
  • The cases are used to discuss the consequences for therapy and prognosis resulting from the heterogeneity of this tumor entity; the relevant immunohistochemical markers used to distinguish between various tumor subtypes of gastrointestinal mesenchymal tumors (GIMT) are listed.
  • The third case of a 40-year-old patient with a malignant GIST recurrence after surgery and exhibiting secondary resistance after one year of successful therapy with the receptor tyrosine kinase inhibitor imatinib (Gleevec), antagonizing pathogenetically relevant constitutive c-KIT activation, illustrates the potential and limitations of the only effective drug treatment for advanced GIST.
  • [MeSH-major] Abdominal Pain / etiology. Cardia. Esophageal Neoplasms / diagnosis. Gastrointestinal Hemorrhage / etiology. Neoplasms, Connective Tissue / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Benzamides. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Esophagectomy. Female. Gastrectomy. Gastric Mucosa / pathology. Gastroscopy. Humans. Imatinib Mesylate. Incidental Findings. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Piperazines / therapeutic use. Polyps / diagnosis. Polyps / drug therapy. Polyps / pathology. Polyps / surgery. Prognosis. Proto-Oncogene Proteins c-kit / analysis. Pyrimidines / therapeutic use. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Shock, Hemorrhagic / etiology. Stromal Cells / pathology. Tomography, X-Ray Computed. Treatment Outcome


9. Okamura H, Fujiwara H, Suchi K, Okamura S, Umehara S, Konishi H, Todo M, Kubota T, Ichikawa D, Kikuchi S, Okamoto K, Kuriu Y, Ikoma H, Nakanishi M, Ochiai T, Sakakura C, Kokuba Y, Sonoyama T, Otsuji E: [Surgically resected local recurrence after endoscopic submucosal dissection of esophageal cancer--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2448-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 66-year-old man was admitted to our hospital because of further examination and a treatment of superficial esophageal cancer.
  • A type 0-IIb+IIa cancer occupying the whole circumference of the lumen of the middle to lower esophagus was revealed.
  • Pathological diagnosis was squamous cell carcinoma, moderately differentiated, the depth of tumor invasion was T1a-LPM.
  • Then, he was diagnosed as the local recurrence of the squamous cell carcinoma of the esophagus.
  • Thoraco-abdominal esophagectomy reconstructed by stomach tube via a retrosternal route was undergone.
  • After the operation, he is receiving adjuvant chemotherapy and alive without recurrence.
  • When endoscopic resection of the esophageal cancer is performed to the lesion, which relatively indicated to endoscopic resection or outside the guideline criteria for endoscopic resection, it is important that we choose the appropriate treatment protocol obtaining an informed consent from the patient sufficiently.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Male. Neoplasm Recurrence, Local / surgery. Reoperation

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037452.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Nettesheim O, Höffken G, Gahr M, Breidert M: [Haematemesis and dysphagia in a 20-year-old woman with congenital spine malformation and situs inversus partialis]. Z Gastroenterol; 2003 Apr;41(4):319-24
Hazardous Substances Data Bank. PHENOXYBENZAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hämatemesis und Dysphagie bei 20 Jahre alter Frau mit kongenitalem kaudalen Regressionssyndrom und Situs inversus partialis.
  • A 20-year-old woman with a four-week history of dysphagia, weight loss of four kilograms and unspecific abdominal pain was admitted because of sudden haematemesis.
  • Upper endoscopy demonstrated a 4 cm large, exophytically growing necrotic tumour of the oesophagus.
  • The CT scan showed a space occupying tumour of the oesophagus and metastases in a size of 1.5 cm in both lungs.
  • Histology of the tumour biopsies showed a poor differentiated squamous cell carcinoma.
  • Staging after the 6 th dose cisplatin (100 mg/m2/die) and 5-fluorouracil (5 x 1000 mg/m2/die) showed a mild reduction of the tumour and the metastases.
  • The patient died ten months later of multiorgan failure after severe progress of tumour and metastatic growth.
  • The manifestation of squamous cell carcinoma of the oesophagus is unusual in people at the age of twenty.
  • Genetic and chromosomal analysis of the patient gave no evidence for a hereditary disorder.
  • Drug history revealed that the patient had been treated with the alpha-receptor blocking drug phenoxybenzamine over at least 12 years for bladder dysfunction.
  • By the German admission board phenoxybenzamine is only recommended for short term therapy.
  • It seems to be likely that even in humans phenoxybenzamine acts as a mutagenic substance and should be carefully used in long-term treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Deglutition Disorders / etiology. Esophageal Neoplasms / diagnosis. Hematemesis / etiology. Kyphosis / congenital. Lung Neoplasms / secondary. Neural Tube Defects / diagnosis. Scoliosis / congenital. Situs Inversus / diagnosis. Spina Bifida Occulta / diagnosis
  • [MeSH-minor] Adrenergic alpha-Antagonists / adverse effects. Adrenergic alpha-Antagonists / therapeutic use. Adult. Biopsy. Esophagus / pathology. Female. Humans. Long-Term Care. Neoplasm Staging. Phenoxybenzamine / administration & dosage. Phenoxybenzamine / adverse effects. Urinary Bladder, Neurogenic / congenital. Urinary Bladder, Neurogenic / drug therapy


11. Osugi H, Takemura M, Morimura K, Kaneko M, Higashino M, Takada N, Lee S, Kinoshita H: Clinicopathologic and immunohistochemical features of surgically resected small cell carcinoma of the esophagus. Oncol Rep; 2002 Nov-Dec;9(6):1245-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical features of surgically resected small cell carcinoma of the esophagus.
  • Esophageal small cell carcinoma (SmC) is considered an aggressive cancer carrying a poor prognosis, although the rarity of this tumor has impeded statistical evaluation.
  • We reviewed records of 457 esophageal cancer patients treated in our department from 1986 to 2000, comparing clinicopathologic factors and post-treatment outcomes, for 9 patients with SmC, most undergoing esophagectomy including lymphadenectomy, with data from 128 patients with esophageal squamous cell carcinoma (SqC) invading to the muscular layer or beyond.
  • All SmC patients had lymph node metastasis (thoracic nodes, 9 patients: abdominal 6; cervical 1).
  • While SmC shows aggressive behavior and worse outcomes than SqC, combining esophagectomy with chemotherapy or radiotherapy may prolong survival.
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Case-Control Studies. Esophagus / pathology. Female. Humans. Immunoenzyme Techniques. Incidence. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Postoperative Complications. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12375028.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Comandone A, Boglione A: Biology, diagnosis and therapeutic options in gastrointestinal stromal tumours. Minerva Chir; 2005 Aug;60(4):197-203

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology, diagnosis and therapeutic options in gastrointestinal stromal tumours.
  • Gastrointestinal stromal tumours (GIST) are the most common form of mesenchymal tumour of the intestinal tract.
  • The incidence in Italy is approximately 800-1,400 new cases/year; the most common localization is the stomach (50-60%), small bowel (20-30%), rectum (10%) and esophagus (5%).
  • Extra-abdominal localizations are very rare.
  • Most GIST have a mutation in kit receptor which becomes constitutive for the neoplasm.
  • Surgery is the mainstay of the therapy mainly in primary tumour.
  • In this situation imatinib mesilate, a tyrosine kinase inhibitor, is the drug of choice which has changed the natural history of the disease.
  • New drugs are now under evaluation in order to prolong the pharmacological activity of tyrosine kinase inhibition after progression of the disease.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166919.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 18
  •  go-up   go-down


13. Benhidjeb T, Moesta KT, Schlag PM: [Staging and neoadjuvant therapy of squamous cell carcinoma of esophagus]. Ther Umsch; 2001 Mar;58(3):165-73
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Staging and neoadjuvant therapy of squamous cell carcinoma of esophagus].
  • [Transliterated title] Staging und neoadjuvante Therapie des Plattenepithelkarzinoms des Osophagus.
  • Once the diagnosis of esophageal cancer is established, the decision on treatment will depend on the stage of the disease.
  • Since improvement of prognosis can only be expected in patients with complete removal of their tumor, preoperative staging plays a pivotal role in the decision-making process.
  • Preoperative diagnostic procedures should define the tumor in its relation to the tracheal bifurcation (site), determine the depth of tumor invasion (T status), evaluate regional lymph node metastases (N1 disease) and exclude distant metastases (M1 disease).
  • A higher accuracy rate may be achieved by combining endosonography with other staging modalities such as computed tomography.
  • Chest x-ray, and percutaneous ultrasonography (abdominal, neck) form the diagnostic basis in staging M1 disease.
  • Computed tomography (neck, chest and abdomen) is currently the best method to detect metastases in the liver and in celiac nodes.
  • Staging laparoscopy when combined with laparoscopic ultrasonography shows a higher sensitivity than ultrasonography and computed tomography in the diagnosis of smaller metastases and peritoneal seedings.
  • En bloc esophagectomy together with the regional lymph nodes remains the treatment of choice in medically fit patients with localized esophageal carcinoma (Stage I-IIB, T1-T2/N0-N1/M0).
  • Most available data indicate that neoadjuvant radiochemotherapy leads in a significant number of patients to downstaging of the tumor, increases the rate of R0 resection, improves local tumor control, and prolongs the recurrence free interval.
  • At present, neoadjuvant therapy is still experimental and there is no consensus for an optimal treatment regimen.
  • Future research must focus on more effective and less toxic neoadjuvant modalities (e.g. new chemotherapy agents, hyperthermia).
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Neoadjuvant Therapy / methods
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Seeding. Neoplasm Staging. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11305155.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 30
  •  go-up   go-down


14. Ueda Y, Shimizu K, Itoh T, Fuji N, Naito K, Shiozaki A, Yamamoto Y, Shimizu T, Iwamoto A, Tamai H, Yamagishi H: Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Jpn J Clin Oncol; 2007 Feb;37(2):140-5
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides.
  • Primary malignant melanoma of the esophagus (PMME) is a very rare disease with an extremely poor prognosis.
  • Surgery is currently considered its best treatment, while any other measures are ineffective.
  • We studied the effect of active specific immunotherapy using monocyte-derived dendritic cells (DCs) pulsed with the epitope peptides of melanoma-associated antigens (MAGE-1, MAGE-3) in patients with PMME after surgery, for the first time.
  • Both patients initially received radical esophagectomy with regional lymphadenectomy, followed by adjuvant chemotherapy with dacarbazine, nimustine, vincristine and interferon-alpha.
  • In the case 1 patient, active specific immunotherapy was used to treat a large abdominal lymph node metastasis that became obvious 21 months after surgery.
  • In the case 2 patient, immunotherapy was tried as post-operative adjuvant treatment after adjuvant chemotherapy.
  • There was no tumor recurrence for 16 months after the immunotherapy.
  • In both patients, the ability of peripheral lymphocytes to produce IFN-gamma in vitro in response to peptide stimulation was significantly enhanced and delayed-type hypersensitivity skin test response to MAGE-3 peptide was turned positive after immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Dendritic Cells / immunology. Esophageal Neoplasms / immunology. Esophageal Neoplasms / therapy. Immunotherapy, Adoptive. Melanoma / immunology. Melanoma / therapy. Neoplasm Proteins / immunology
  • [MeSH-minor] Aged. Combined Modality Therapy. Epitopes. Esophagectomy. Humans. Male. Melanoma-Specific Antigens. Middle Aged

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255158.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Epitopes; 0 / MAGEA1 protein, human; 0 / MAGEA3 protein, human; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


15. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg; 2001 Dec;72(6):1918-24; discussion 1924-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
  • This study examines the morbidity, mortality, and early survival of patients after transthoracic esophagectomy for esophageal carcinoma using current staging techniques and neoadjuvant therapy.
  • The technique includes right thoracotomy, laparotomy, and cervical esophagogastrostomy (total thoracic esophagectomy) with radical mediastinal and abdominal lymph node dissection.
  • Eighty-one percent (202) had induction chemotherapy (all patients with clinical T3/4 or N1).
  • Five patients with tumor in situ, 6 patients with stage IV disease, and 1 patient who could not be staged (12 pts) were excluded from survival and multivariate calculations.
  • CONCLUSIONS: Total thoracic esophagectomy with node dissection for esophageal cancer appears to have acceptable morbidity and mortality with encouraging survival results in the setting of neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrostomy / methods. Lymph Node Excision / methods. Precancerous Conditions / surgery
  • [MeSH-minor] Abdomen / surgery. Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Mediastinum / surgery. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789772.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Bizekis C, Kent MS, Luketich JD, Buenaventura PO, Landreneau RJ, Schuchert MJ, Alvelo-Rivera M: Initial experience with minimally invasive Ivor Lewis esophagectomy. Ann Thorac Surg; 2006 Aug;82(2):402-6; discussion 406-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our standard approach involves laparoscopic and thoracoscopic mobilization of the esophagus with a cervical esophagogastric anastomosis.
  • The planned approach included a totally laparoscopic abdominal procedure and either a minithoracotomy or thoracoscopy.
  • Indications for esophagectomy included short segment Barrett's esophagus with high-grade dysplasia or resectable adenocarcinoma of the gastroesophageal junction (GEJ) with minimal proximal esophageal extension. .
  • Twenty-five patients (50%) received either preoperative chemotherapy or chemoradiation.
  • There was one nonemergent conversion to an open procedure during laparoscopy.
  • Three patients (6%) developed an anastomotic leak; all were successfully managed nonoperatively.
  • Four patients (8%) developed postoperative pneumonia.
  • [MeSH-minor] Adult. Aged. Anastomosis, Surgical. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Postoperative Complications / etiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863737.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Kantarci M, Polat P, Alper F, Eroglu A, Eren S, Okur A, Onbaş O: Comparison of CT and MRI for the diagnosis recurrent esophageal carcinoma after operation. Dis Esophagus; 2004;17(1):32-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of CT and MRI for the diagnosis recurrent esophageal carcinoma after operation.
  • Some reports have suggested that recurrent tumors should be treated aggressively with a combination of chemotherapy and radiotherapy.
  • The aim of this study was to assess the comparative utility of computed tomography (CT) and magnetic resonance imaging (MRI) for the evaluation of recurrence after curative resection of cancer of the esophagus and gastroesophageal junction.
  • To maximize survival benefit, detection of tumor recurrence as early and accurately as possible is important.
  • Twenty-three patients who developed recurrent tumors after curative transthoracic esophagogastrectomy for esophageal carcinoma were analyzed retrospectively.
  • Primary tumor recurrence was detected at the anastomosis side in 19 patients (intraluminal mass in 13 and as diffuse or focal wall thickening in six).
  • Distant recurrence was seen in the liver (n = 5), lung (n = 4), bone (n = 3), abdominal lymph node (n = 4), pleural effusion (n = 2) and pericardial effusion (n = 1).
  • Thickening of esophageal wall was demonstrated in nine patients using CT, but only seven of these tumor recurrences were confirmed by MRI, the remaining two were related to secondary fibrosis.
  • Both CT and MRI showed diffuse gastric wall thickening determined as false tumor recurrence due to severe gastritis in one case.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 ISDE
  • (PMID = 15209738.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Stilidi I, Davydov M, Bokhyan V, Suleymanov E: Subtotal esophagectomy with extended 2-field lymph node dissection for thoracic esophageal cancer. Eur J Cardiothorac Surg; 2003 Mar;23(3):415-20
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty-six patients were operated on for cancer of the midthoracic esophagus, 48 for cancer of the lower thoracic esophagus, and 13 for cancer of the aortal segment of the esophagus.
  • No patient had received chemotherapy or radiotherapy before operation.
  • Positive abdominal and/or mediastinal lymph nodes were found in 122 patients (82.9%).
  • Even in T(1)-T(2) tumors mediastinal or abdominal lymph nodes are involved in up to 80% of cases.
  • Effective multimodality treatment may be helpful for patients with advanced disease.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12614816.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement